Biocept enters into agreement with healthcare network

Biocept announces that it has entered into an agreement with a large integrated healthcare delivery network to evaluate the clinical utility and cost effectiveness of using Biocept’s Target Selector testing in patients diagnosed with non-small cell lung cancer, or NSCLC. As part of the agreement, the Company’s liquid biopsy testing will be used to profile patients who have been diagnosed with NSCLC and/or have progressed on EGFR targeted therapy. Key objectives of the collaboration are to evaluate improvements in the molecular profiling rate of advanced NSCLC patients and the reduction of the overall cost of patient care

https://bit.ly/2ONtzn8